Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2020 Nov 11;20(1):11–25. doi: 10.1158/1535-7163.MCT-20-0563

Figure 2. Transcriptional activity of well-characterized estrogen-responsive genes TFF1 and GREB1 in WT MCF-7:WS8 and LTED endocrine-resistant MCF-7:5C with test compounds.

Figure 2.

A, mRNA expression of TFF1 (or pS2) in MCF-7:WS8 cells after 24-hour-treatment with 1 nM E2, and 1 μM for other test compounds. B, mRNA expression of GREB1 in MCF-7:WS8 cells after 24-hour-treatment with 1 nM E2, and 1 μM for other test compounds. C, mRNA expression of TFF1 in MCF-7:5C cells after 24-hour-treatment with 1 nM E2, and 1 μM for other test compounds. D, mRNA expression of GREB1 in MCF-7:5C cells after 24-hour-treatment with 1 nM E2, and 1 μM for other test compounds.